Abstract PS14-16: Novel iodine nanoparticle micro-localization and resultant radiotherapy-enhancement of triple negative human breast cancer growing in the brains of athymic nude mice

2021 ◽  
Author(s):  
Sharif M Ridwan ◽  
James F Hainfeld ◽  
Yaroslav Stanishevskiy ◽  
Vanessa Ross ◽  
Henry M Smilowitz
Keyword(s):  
Breast Cancer ◽  
Nude Mice ◽  
Human Breast Cancer ◽  
Triple Negative ◽  
Human Breast ◽  
Athymic Nude Mice

scholarly journals Physiological Concentrations of Dietary Genistein Dose-Dependently Stimulate Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) Tumors Implanted in Athymic Nude Mice

2001 ◽  
Vol 131 (11) ◽  
pp. 2957-2962 ◽  
Author(s):  
Young H. Ju ◽  
Clinton D. Allred ◽  
Kimberly F. Allred ◽  
Kimberly L. Karko ◽  
Daniel R. Doerge ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nude Mice ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Athymic Nude Mice ◽  
Mcf 7

scholarly journals Dietary stearate reduces human breast cancer metastasis burden in athymic nude mice

2009 ◽  
Vol 26 (5) ◽  
pp. 415-424 ◽  
Author(s):  
Lynda M. Evans ◽  
Eric C. Toline ◽  
Renee Desmond ◽  
Gene P. Siegal ◽  
Arig Ibrahim Hashim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nude Mice ◽  
Human Breast Cancer ◽  
Cancer Metastasis ◽  
Breast Cancer Metastasis ◽  
Human Breast ◽  
Athymic Nude Mice

scholarly journals Iodine nanoparticle radiotherapy of human breast cancer growing in the brains of athymic mice

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
James F. Hainfeld ◽  
Sharif M. Ridwan ◽  
F. Yaroslav Stanishevskiy ◽  
Henry M. Smilowitz
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Enhancement Factor ◽  
Triple Negative ◽  
X Rays ◽  
Breast Cancers ◽  
Human Breast ◽  
Local Tumor ◽  
Athymic Nude Mice ◽  
The Brain

Abstract About 30% of breast cancers metastasize to the brain; those widely disseminated are fatal typically in 3–4 months, even with the best available treatments, including surgery, drugs, and radiotherapy. To address this dire situation, we have developed iodine nanoparticles (INPs) that target brain tumors after intravenous (IV) injection. The iodine then absorbs X-rays during radiotherapy (RT), creating free radicals and local tumor damage, effectively boosting the local RT dose at the tumor. Efficacy was tested using the very aggressive human triple negative breast cancer (TNBC, MDA-MB-231 cells) growing in the brains of athymic nude mice. With a well-tolerated non-toxic IV dose of the INPs (7 g iodine/kg body weight), tumors showed a heavily iodinated rim surrounding the tumor having an average uptake of 2.9% iodine by weight, with uptake peaks at 4.5%. This is calculated to provide a dose enhancement factor of approximately 5.5 (peaks at 8.0), the highest ever reported for any radiation-enhancing agents. With RT alone (15 Gy, single dose), all animals died by 72 days; INP pretreatment resulted in longer-term remissions with 40% of mice surviving 150 days and 30% surviving > 280 days.

Sign in / Sign up

Export Citation Format

Share Document